Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Breast Neoplasms 10Prostatic Neoplasms 8Colonic Neoplasms 7Neoplasms 5Colorectal Neoplasms 5Multiple Myeloma 4Smoldering Multiple Myeloma 3Monoclonal Gammopathy of Undetermined Significance 3Lung Neoplasms 3Uterine Cervical Neoplasms 2Uterine Cervical Dysplasia 2Stomach Neoplasms 2Rectal Neoplasms 2Radiodermatitis 2Pancreatic Neoplasms 2Pain 2Esophageal Neoplasms 2Breast Carcinoma In Situ 2Adenomatous Polyposis Coli 2cyclopia sequence 1Uterine Neoplasms 1Tuberous Sclerosis 1Thrombocythemia, Essential 1Stomatitis 1Sezary Syndrome 1Seizures 1Psychological Well-Being 1Prostate Cancer Metastatic Castration Resistant 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cyclophosphamide 184fludarabine phosphate 162fludarabine 128Busulfan 116Tacrolimus 109Mycophenolic Acid 101Whole-Body Irradiation 97Antilymphocyte Serum 87Peripheral Blood Stem Cell Transplantation 84Azacitidine 82Melphalan 81Filgrastim 74Cytarabine 74Cyclosporine 72Methotrexate 64Decitabine 57Granulocyte Colony-Stimulating Factor 51Thiotepa 45Radiotherapy 41thymoglobulin 40Stem Cell Transplantation 40Cord Blood Stem Cell Transplantation 40venetoclax 39Clofarabine 35Sirolimus 30Methylprednisolone 30Specimen Handling 27Etoposide 24Alemtuzumab 24Biopsy 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myelodysplastic Syndromes × Curcumin × Clear all
NCT06063486 2026-03-27

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

University of Southern California

Phase 2 Recruiting
30 enrolled
Myeloid

Myelodysplastic Syndromes, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡